THE BULLETIN - 29 May 2024

Editor’s note: This article is part of a collection of expert commentaries. You can read the rest of the series here. 

The world is seeing an increase in disease outbreaks that underscore the critical importance of robust biosafety and biosecurity measures in pathogen research. We are emerging from a COVID-19 pandemic that has left a trail of economic devastation throughout the world, and more similar crises are almost guaranteed. These will inevitably affect Africa perhaps more than any other region. After all, the continent grapples with around 80 disease outbreaks a year. Moreover, these are coupled with a perpetual risk that novel diseases will emerge—which is increasingly likely as Africa’s population and global interconnectedness grow and the environment continues to degrade.

These outbreaks, are always swiftly followed by research to understand disease pathogens and to protect humanity, therefore making the responsible conduct of enhanced potential pandemic pathogen (ePPP) research a paramount concern. This research involves experimentally altering potential pandemic pathogens in ways that can alter attributes such as transmissibility and virulence, it’s sometimes called “gain of function” research. Yet gaps still exist in human resources (a particularly acute problem for African institutions); financing; procurement of laboratory supplies and parts; and scheduled audits to sustain biosafety levels.

A lack of national regulations for the design and construction of biosafety level (BSL) laboratories in Africa, has left this expertise elsewhere. Only one country out of the 11 African countries in the Emerging and Dangerous Pathogen Laboratory Network surveyed by the World Health Organization in 2016, for example, had national regulations for the design and construction of BSL-3 laboratories. This is not ideal.

Why are these labs necessary? Pathogen research enables in-depth understanding of the characteristics of different disease agents, such as viruses, bacteria, and fungi and is essential for informing public health efforts such as the development of diagnostic, prevention, and treatment strategies. However, in research, sometimes scientists need to study viruses that are hard to grow in labs or animals. To do this, they might use parts from a different virus that’s easier to grow to create a new virus. This method of studying viruses is deemed safe because the new virus can’t spread further as it lacks the necessary genetic instructions to reproduce itself inside a host cell. There is, however, a risk that the new virus could become highly contagious and more harmful if its genes change and it becomes able to spread beyond one cycle of growth. Typically, research on enhanced potential pandemic pathogens is conducted in high biosafety laboratories, such as BSL-3 labs.

RELATED:

The risks of underdeveloped biorisk management policies in pandemic hotspots

BSL-3 labs are specifically designed to handle dangerous pathogens, including those that can cause serious or deadly diseases through inhalation such as SARS-CoV-2. These laboratories play a crucial role in public health and scientific research. Increasing the number of BSL-3 laboratories in Africa would enhance the region’s capacity to detect, respond to, and prevent infectious diseases, ultimately contributing to global health security. Disease outbreaks are very difficult to contain in settings where appropriate research infrastructure such as BSL-3 facilities does not exist. An example of the problem: During the recent mpox outbreak in the Democratic Republic of Congo (DRC), in which more than 19,000 people were suspected to have been infected, very few cases were confirmed through laboratory testing.

It is imperative to ensure that research adheres to strict biosafety regulations and that there is stringent oversight at both institutional and national levels. The European Union and the United States have robust regulations for conducting enhanced potential pandemic pathogen research. However, this is not the case in Africa, which calls for the need for relevant regional and governmental bodies to put in place laws, rules, regulations, and codes of conduct that address inherent biosafety and biosecurity risks and ensure responsible conduct of such research.

These regulations need to include risk-benefit assessment of enhanced potential pandemic pathogen research and clearly outline the criteria for such an assessment. In addition to having regional and national regulations in place, institutions conducting such research also need to have specific biorisk management and research review processes that are aligned to regional and national regulations. Oversight in the form of laboratory audits and other mechanisms should be enforced to safeguard communities from potential risks associated with enhanced potential pandemic pathogens research. The onus is not only on regulators and institutions, but on funders that can ensure those awarded grants are encouraged to promote biosafety.

RELATED:

TB studies illustrate the importance of properly assessing the risks of pathogen research

At the Science for Africa Foundation, we are funding huge networks that handle pathogens. To further biosafety and biosecurity in Africa, we’re sharing the Bulletin’s A Framework For Tomorrow’s Pathogen Research report, which contains considerations for research with dangerous pathogens. One of us (Tom Kariuki) worked on it as part of the organization’s Pathogen Project Task Force. Independent reviewers of our grants will keep in mind the recommendations of the task force, as public safety is paramount to us.

Responsible conduct of enhanced potential pandemic pathogen research in Africa demands concerted efforts to harmonize regulations at both regional and national levels, bolstered by stringent oversight mechanisms. By prioritizing biosafety and biosecurity measures and ensuring adherence to regulations, we can safeguard public health and mitigate the risks associated with pathogen research on the continent.

This article was produced with the support of Deborah-Fay Ndlovu, Acting Head of Corporate and Science Communication at the SFA Foundation.

About the Author(s)

DENIS CHOPERA

Medical virologist and a programme manager

Tom Kariuki

CEO and Board Secretary, SFA Foundation